Plain-English translation of NCT07557056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and —two medications that work in different ways to fight cancer cells—are effective when given together as a first treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if this combination can help patients achieve very deep remission, where cancer cells become undetectable in the blood. The study will also track how safe this medication combination is and how it affects quality of life.
Currently, patients with CLL or SLL often receive older chemotherapy treatments or single medications. This trial exists because researchers believe that combining these two newer medications—which target cancer cells through different mechanisms—might work better than current standard treatments, potentially giving patients longer periods without needing additional therapy.
You likely qualify if…
You likely don't qualify if…
You will take as a daily oral pill for the entire study. Starting in the third month, you will also begin taking daily. Treatment continues for up to 14 months (14 cycles of 28 days each) unless your disease progresses or side effects become too severe. Throughout the trial, you'll have regular clinic visits for blood tests, CT scans, and bone marrow biopsies to monitor how well the treatment is working and check for side effects. You'll also complete surveys about your fatigue and quality of life.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States